Advertisment

Promising Results from Brazilian Trial of Butantan Dengue Vaccine

author-image
Dr. Jessica Nelson
New Update
NULL

Promising Results from Brazilian Trial of Butantan Dengue Vaccine

Advertisment

A New Hope in the Fight Against Dengue

Advertisment

Dengue, a mosquito-borne viral infection, affects an estimated 390 million people worldwide each year. The disease, prevalent in tropical and subtropical regions, has been a significant public health concern for decades. However, recent developments in vaccine research offer a glimmer of hope. A live, attenuated, tetravalent vaccine, known as the Butantan Dengue Vaccine (Butantan DV), has shown promise in a large-scale trial conducted in Brazil.

Unveiling the Butantan Dengue Vaccine

Developed by the Butantan Institute in Brazil, the Butantan DV is a single-dose vaccine designed to combat all four serotypes of the dengue virus. The development of this vaccine began in 2010, with support from FAPESP and NIH. This tetravalent vaccine is now in its phase 3 of clinical trials, marking a significant milestone in the fight against dengue.

Advertisment

Impressive Results from Large-Scale Trial

A double-blind trial, involving 16,235 participants, was conducted over a three-year enrollment period to evaluate the overall efficacy and safety of the Butantan DV. The participants received either the Butantan DV or a placebo. The results have been encouraging. The overall two-year vaccine efficacy was found to be 79.6% among participants with no evidence of previous dengue exposure and 89.2% among those with a history of exposure. The vaccine's efficacy against DENV 1 was 89.5% and against DENV 2 was 69.6%.

Benefits for All Age Groups

Advertisment

The Butantan DV has been proven to be safe and effective for all age groups between 2 and 59, and for people with or without a prior history of dengue infection. Its single-dose scheme also offers several advantages over other available vaccines. Not only does it make the vaccination process more straightforward, but it also increases the likelihood of individuals completing their vaccination, thereby enhancing community-wide immunity.

Safety of the Vaccine

The trial also monitored solicited systemic vaccine or placebo-related adverse events within 21 days after injection. Adverse events were more common with Butantan DV than with the placebo, occurring in 58.3% of the vaccine recipients compared to 45.6% of those who received the placebo. However, these events were generally mild and manageable, indicating that the vaccine is safe for use.

Future Perspectives

The Butantan Institute expects to complete the final phase of research later this year. With the vaccine's impressive performance in the trial so far, there is potential for it to be used in a campaign against dengue as early as 2025. This development represents a significant stride in the global fight against dengue, bringing us one step closer to reducing the burden of this debilitating disease.

Advertisment
Chat with Dr. Medriva !